City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border 		  
   
The following is a list of available studies directed by  Maria Delioukina, MD  
Search results:  4  Clinical trial(s) found  (Page 1 of 1 )
 
Click here to generate a printer-friendly view  
 09045
   P.I.: Maria Delioukina, MD (NCI Approved External Peer Review)
Title: A Phase II Study of 5-Fluoro-2-deoxycytidine with Tetrahydrouridine (FdCyd + THU) in Myeloid Leukemia and MDS
 
Click here for  Full Eligibility Criteria
 08219
   P.I.: Maria Delioukina, MD (Industrial)
Title: A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T- Cell Lymphoma
 
Click here for  Full Eligibility Criteria
 07043
   P.I.: Maria Delioukina, MD (Industrial)
Title: A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies
 
Click here for  Full Eligibility Criteria
 07003
   P.I.: Maria Delioukina, MD (Industrial)
Title: A Phase I Study of Alefacept (Amevive) in the Treatment of Cutaneous-T-Cell Lymphoma and Peripheral T-Cell NHL
 
Click here for  Full Eligibility Criteria
 

  
© 2009 City of Hope.
1500 East Duarte Road
Duarte, California 91010
626-256-HOPE (4673)
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and urology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.